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Value of the CRP–albumin ratio in patients with resectable
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Abstract : Background : The C-reactive protein (CRP)–albumin ratio (CAR) was reported as a prognostic factor of 
resectable hepatocellular carcinoma. The aim of this study was to analyse the significance of CAR in resectable 
pancreatic cancer. Patients and Methods : 163 patients with curative resection for pancreatic cancer were en-
rolled in this retrospective study. Cases of non-curative resection were excluded. The CAR was calculated with 
the preoperative plasma CRP and albumin values, with a cut-off value of 0.06, as calculated in a previous report. 
Results : Patients in the low CAR group had significantly better overall survival (OS) and disease-free survival 
(DFS) compared with the high CAR group (P < 0.05). On multivariate analysis, for high CAR, CA19-9 > 300 U / ml 
and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. High CAR was significant-
ly associated with advanced T stage. Conclusion : The CAR might be a prognostic factor for patients with resect-
able pancreatic cancer. J. Med. Invest. 68 : 244-248, August, 2021
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INTRODUCTION
 
The prognosis of patients with pancreatic ductal adenocar-
cinoma (PDAC) is extremely poor. Despite the development of 
surgical techniques and perioperative chemotherapy, the 5-year 
survival rate is 8% in the United States (1). PDAC is also the 
fifth most common cause of cancer death in Japan (2). The 
frequency of postoperative recurrence remains high in patients 
with PDAC (3) ; therefore, a novel prognostic marker to predict 
recurrence is required. 
Nowadays, tumour-related pathological factors have been 
identified as predictive markers in patients with PDAC, in-
cluding tumour stage, lymph node metastasis, vascular and 
lymphatic invasion and perineural invasion. Several predictive 
markers based on preoperative systemic inflammation and nu-
tritional status such as the neutrophil–lymphocyte ratio (NLR), 
platelet–lymphocyte ratio (PLR), modified Glasgow prognostic 
score (mGPS), and prognostic index (PNI) were reported in lung 
cancer (4), hepatocellular carcinoma (5), melanoma (6), renal cell 
carcinoma (7), gastric cancer (8), intrahepatic cholangiocarcino-
ma (9) and colorectal cancer (10). These factors has been report-
ed as useful biomarker to predict the prognosis in PDAC (11, 12). 
C-reactive protein (CRP) to albumin ratio is based on two 
acute inflammatory protein (13). The CRP–albumin ratio (CAR) 
was reported as a prognostic factor of resectable hepatocellular 
carcinoma, colorectal cancer, oesophageal cancer, gastric cancer, 
renal cancer, and pancreatic cancer (14-18). 
The aim of this study was to analyse and validate the signifi-
cance of the CAR in resectable pancreatic cancer at our hospital. 
PATIENTS AND METHODS
One hundred sixty-three patients who underwent curative 
surgical resection for PDAC during 2004 to 2018 at the University 
of Tokushima Hospital were enrolled in this retrospective study. 
Fourteen patients were excluded because of non-curative resec-
tion. All the patients had PDAC proven histologically. Finally, 
149 patients were analysed in this study. Laboratory data in-
cluding serum CRP and albumin were collected within 1 month 
before surgery. Patients were followed up monthly for tumour 
markers including CEA and CA19-9 and underwent computed 
tomography every 4–6 months. When recurrence was suspected, 
precise diagnostic imaging studies including positron emission 
tomography were performed. After confirmation of recurrent 
pancreatic cancer, systemic chemotherapy, radiation therapy, 
or best supportive care were indicated. The clinicopathological 
characteristics of the patients are shown in Table 1. All patients 
signed informed consent for this study, which was approved by 
the clinical ethics committee at our institution (#3362).
The NLR, PNI, PLR, and mGPS were calculated with cut-
off values of 3, 45, 150, and 1, respectively. The CAR was also 
calculated. To determine the appropriate cutoff value of CAR, 
receiver operation characteristic (ROC) curve analysis was 
performed. The cutoff value of CAR was 0.06 and the AUC value 
was 0.54223. 
Statistical analysis
Statistical comparisons for significance were made using chi-
squared test or Fisher’s exact test with one degree of freedom, 
as appropriate. Cumulative patient survival and recurrence-free 
survival were determined using the Kaplan–Meier method with 
a log-rank test. Univariate and multivariate analyses were 
performed using a Cox proportional hazard model. A P-value of 
less than 0.05 was considered statistically significant. Statistical 
analysis was performed with JMP 14 software (SAS Institute, 
Cary, NC, USA).  
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RESULTS
Comparison of prognostic factors for overall survival (OS) in pa-
tients with surgical resection for PDAC
The OS rate was significantly worse in patients with a high 
CAR compared with those with a low CAR (Figure 1A). The 
prognostic factors for OS in patients with surgical resection for 
PDAC is shown in Table 2. In the univariate analysis, seven 
factors were independent prognostic factors for OS including 
CAR (HR 2.826, 95% CI 1.720–4.645, P < 0.001), PNI (HR 
2.250, 95% CI 1.384–3.645, P = 0.0007), PLR (HR 1.643, 95% 
CI 1.022–2.684, P = 0.0045), CA19-9 (HR 2.085, 95% CI 1.314–
3.311, P = 0.0013), adjuvant chemotherapy (HR 2.208, 95% CI 
1.396–3.491, P = 0.0022), T3+4 (HR 2.873, 95% CI 1.700–5.114, 
P < 0.001), and lymph node metastasis (HR 1.846, 95% CI 1.143–
2.945, P = 0.0095). In the multivariate analysis of these seven 
factors, three factors were independent prognostic factors for OS 
including CAR (HR 2.668, 95% CI 1.523–4.672), CA19-9 (HR 
2.011, 95% CI 1.213–3.334), and adjuvant chemotherapy (HR 
2.231, CI 1.379–3.609). 
Comparison of prognostic factors for disease-free survival (DFS) in 
patients with surgical resection for PDAC
The DFS rate was significantly worse in patients with a high 
CAR compared with those with a low CAR (Figure 1B). The 
prognostic factors for DFS with surgical resection for PDAC 
are shown in Table 3. In the univariate analysis, five factors 
were independent prognostic factors for DFS including CAR 
(HR 2.826, 95% CI 1.720–4.645, P < 0.001), PNI (HR 1.542, 
95% CI 1.008–2.340, P = 0.0308), CA19-9 (HR 1.864, 95% CI 
1.239–2.797, P = 0.0031), adjuvant chemotherapy (HR 1.884, 
95% CI 1.257–2.824, P = 0.0020), and T(3+4) (HR 1.890, 95% CI 
1.232–2.966, P = 0.0032). In the multivariate analysis of these 
five factors, three factors were independent prognostic factors for 
DFS including CAR (HR 1.990, 95% CI 1.198–3.307, P = 0.0103), 
CA19-9 (HR 1.864, 95% CI 1.239–2.797, P = 0.0083), and adju-
vant chemotherapy (HR 1.884, 95% CI 1.257–2.824, P = 0.0032). 
Table 1.　Clinicopathological characteristics of patients with surgi-
cal resection for pancreas ductal adenocarcinoma
Parameters
Age, years 70 (63-76)
female / male 77 (51.7) / 72 (48.3)
Body mass index kg / m2 22.1 (19.7-24.2)
Fibrinogen, g / ml 439 (367-510)
C reactive protein, mg / L 0.09 (0.05-0.27)
Serum albumin, g / dl 3.9 (3.7-4.2)
WBC, 109 / L 5450 (4400-6600)
Neutrophils, 109 / L   3650 (2600-4495)
Lymphocytes, 109 / L 1290 (1040-1715)
CEA ng / ml 2.3 (1.4-3.9)
CA19-9 U / ml 126 (27.5-670)
Type of resection (DP / PD / TP) 40 / 56 / 4
PV resection (n, %) 22 (14.7)
Neoadjuvant chemotherapy (n, %) 16 (10.7)
Postoperative chemotherapy (n, %) 89 (59.3)
UICC stage (n, %)
 ⅠA 20 (15.4)
 ⅠB 16 (16)
 ⅡA 47 (31.5)
 ⅡB 43 (28.9)
 Ⅲ 23 (15.4)
Resection margin R0 115 (76.7)
Tumor size ≥ 2cm 113 (75.6)
Lymph node metastasis (n) 52 (35.1)
Lymphatic invasion (ly) 100 (68.0)
Vascular invasion (v) 114 (77.6)
Perineural invasion (ne) 119 (81.5)
Anterior serosal invasion (s) 34 (29.6)
Retroperitoneal invasion (rp) 45 (38.1)
Microscopic portal vein invasion (pv) 23 (22.3)
Microscopic arterial invasion (a) 6 (5.7)
Plexus invasion (pl) 11 (12.5)
Data are expressed as median (IQR) or n(%) Figure 1.　Kaplan–Meier curves of overall survival and disease-
free survival according to CAR. (A) Overall survival. (B) Disease-free 
survival.
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Clinicopathological features according to the CAR
Clinicopathological factors were compared between the high 
CAR and low CAR groups in Table 4. The high CAR group was 
correlated with higher CRP, lower serum albumin, higher serum 
fibrinogen, low LCR, high NLR, low PNI and high mGPS. In the 
tumour-related factors, the high CAR group was significantly 
associated with T (3+4). Also, the high CAR group showed an 
association with portal vein resection and adjuvant chemother-
apy but this was not significant. The other factors showed no 
significant difference between these two groups.
 
Table 2.　OS related variables
Univariate Multivariate
Factor p-value HR (95% CI) p-value HR (95% CI)
CAR  < 0.06 / ≥ 0.06 < 0.001 2.826 (1.720-4.645) 0.0006 2.668 (1.523-4.672)
LCR < 15090 / ≥ 15090 0.0505 1.593 (0.390-1.007)
NLR < 3 / ≥3 0.941 1.021 (0.603-1.672)
PNI < 45 / ≥ 45 0.0007 2.250 (1.384-3.645) 0.3571 1.282 (0.755-2.175)
PLR < 150 / ≥ 150 0.0045 1.643 (1.022-2.684) 0.6254 1.139 (0.675-1.923)
mGPS 0 / 1,2 0.6799 2.270 (0.806-5.190)
Gender Female / male 0.7023 1.315 (0.829-2.087)
Age < 70 / ≥ 70 0.1558 1.391 (0.874-2.201)
BMI kg / m2 < 25 / ≥ 25 0.5203 1.216 (0.639-2.143)
CEA ng / ml < 5 / ≥ 5 0.5878 1.203 (0.578-2.248)
CA19-9 U / ml < 300 / ≥ 300 0.0013 2.085 (1.314-3.311) 0.0068 2.011 (1.213-3.334)
Resection type PD / DP / TP 0.4474 1.190 (0.726-1.951)
PV resection No / yes 0.4731 1.310 (0.575-2.600)
NAC(-) No / yes 0.9223 1.039 (0.433-2.116)
AC(-) No / yes 0.0022 2.208 (1.396-3.491) 0.0011 2.231 (1.379-3.609)
T(3+4) No / yes < 0.001 2.873 (1.700-5.114) 0.0870 1.539 (0.906-3.166)
N(+) No / yes 0.0095 1.846 (1.143-2.945) 0.0987 1.693 (0.906-3.166)
Table 3.　DFS related variables
Univariate Multivariate
Factor p-value HR (95% CI) p-value HR (95% CI)
CAR  <0.06 / ≥ 0.06 < 0.001 2.826 (1.720-4.645) 0.0103 1.990 (1.198-3.307)
LCR <15090 / ≥ 15090 0.0030 1.843 (0.357-0.822)
NLR < 3 / ≥ 3 0.3812 1.176 (0.759-1.792)
PNI < 45 / ≥ 45 0.0308 1.542 (1.008-2.340) 0.6387 1.113 (0.708-1.735)
PLR < 150 / ≥ 150 0.2235 1.270 (0.840-1.928)
mGPS (0 / 1+2) 0 / 1,2 0.0529 1.956 (0.662-4.642)
Gender (F / M) Female / male 0.9196 1.040 (0.698-1.553)
Age > 70 < 70 / ≥ 70 0.4904 1.176 (0.780-1.759)
BMI > 25 kg / m2 < 25 / ≥ 25 0.3700 1.295 (0.729-2.158)
CEA > 5 ng / ml < 5 / ≥ 5 0.1032 1.604 (0.886-2.713)
CA19-9 > 300 U / ml < 300 / ≥ 300 0.0031 1.864 (1.239-2.797) 0.0083 1.802 (1.166-2.776)
PD / DP / TP PD / DP / TP 0.4415 1.322 (0.850-2.058)
PV resection No / yes 0.1937 1.466 (0.809-2.478)
NAC(-) No / yes 0.4135 1.306 (0.709-2.405)
AC(-) No / yes 0.0020 1.884 (1.257-2.824) 0.0032 1.884 (1.245-2.851)
T(3+4) No / yes 0.0032 1.890 (1.232-2.966) 0.0646 1.548 (0.974-2.514)
N(+) No / yes 0.0561 1.494 (0.979-2.252)
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DISCUSSION
In this study, OS and DFS were significantly worse in patients 
with resectable PDAC and a high CAR of > 0.06. The CAR 
was an independent prognostic factor for OS and DFS in the 
multivariate analysis. To the best of our knowledge, no study 
has compared other prognostic markers such as lymphocyte to 
CRP ratio (LCR), NLR, PNI, PLR, and mGPS in patients with 
resectable PDAC. 
In our study, the higher value of CAR was correlated with 
other prognostic markers which calculated with CRP and serum 
albumin and it was statistically superior to the other prognostic 
markers. The higher value of CAR was also correlated with high-
er T factor which reflected in local advancement of the pancreatic 
cancer.
The precise mechanism of the relation between the CAR and 
prognosis in patients with resectable PDAC has not been fully 
elucidated yet. Several possible mechanism has been reported in 
basic research articles. Mantovani A et al. reported that the mi-
gration, invasion, and metastasis of cancer cells could contribute 
to the inflammation through the activation of several chemok-
ines such as CXCR4 and its ligand CXCL12 (19) ; as a result, the 
CRP reflects a cancer-specific inflammatory response to tumour 
necrosis or local tissue damage and indicates a favourable envi-
ronment for the establishment and growth of distant metastasis. 
Yang J et al. also reported that CRP binding activated Fcγ recep-
tors and stimulated the PI3K / AKT, ERK, and NFκB pathways 
and inhibited caspase cascade activation induced. CRP also en-
hanced myeloma cell secretion of IL-6 and IL-6-protected myelo-
ma cells resulting from chemotherapy drug-induced apoptosis. 
Therefore CRP could be one of the candidate of new therapeutic 
approach for cancer in basic research (20). 
On the other hand, serum albumin level is low in patients with 
PDAC especially in the perioperative period because of malnutrition 
and cachexia. Improvement of perioperative immune-nutritional 
status reduced post-operative inflammation (21, 22). Poor nu-
tritional state in pancreatic surgery has been reported to be 
associated with worse postoperative survival (11). Therefore, 
the CAR calculated with two critical factors could represent the 
inflammation and nutritional status of PDAC patients. 
Recently, CAR was also reported as one of the poor prognostic 
marker not only in solid cancer but also hematologic cancer such 
as malignant lymphoma (23). Moreover, Araki T et al. reported 
that evaluation of CAR could predict therapeutic response to 
immune check point inhibitor such as nivolumab (24).
There were several limitations to this study. This study was 
retrospective and the sample size was relatively small. Further 
studies using a larger sample size and a prospective approach or 
propensity score matching are required.
In conclusion, the preoperative CAR is a poor prognostic factor 
in patients with resectable PDAC. CAR can be simply calculated 
using preoperative serum CRP and albumin and reflects local 
inflammation caused by invasion of PDAC.
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